Intercept's OCA is the most advanced NASH candidate in development, but the pipeline is crowded.
Following the encouraging news of Ocaliva’s updated label at the start of February, Intercept’s fourth-quarter results were tame in comparison. We are decreasing our fair value estimate for Intercept to $170 per share from $188, primarily to account for increased competition in the NASH market in the out years of our 10-year forecast. We believe Intercept remains significantly undervalued following the market’s read-through of patient deaths among primary biliary cholangitis patients with severe...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.